Avacta has announced the appointment of Dr. Mark Goldberg as a non-executive director. Dr. Goldberg is a medical oncologist and hematologist on the faculty of Brigham & Women's Hospital and Harvard Medical School, a veteran biotech executive and long-time American Cancer Society (ACS) and ACS Cancer Action Network (CAN) volunteer. He is the past-chair of the Eastern New England Area Board of the American Cancer Society and currently serves as a member of its national board of directors. Dr. Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines.